Skip to main content
ELTX
NASDAQ Life Sciences

Elicio Extends Cash Runway to Q4 2026, Reports Positive Phase 2 Trial Observations

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$11.39
Mkt Cap
$217.163M
52W Low
$5.15
52W High
$14.93
52W Position info
121% above low
Off High info
24% below high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

ELTX has more than doubled off its 52-week low of $5.15 on elevated volume (2.4× avg).

Summary

Elicio Therapeutics reported its first quarter 2026 financial results, including an improved net loss per share of $0.65 compared to $0.87 year-over-year. Critically, the company announced an extension of its cash runway into Q4 2026, which is beyond the anticipated mid-year readout for the Phase 2 AMPLIFY-7P trial. This extension was partly supported by raising $13.0 million through its at-the-market (ATM) program in Q1 and Q2 to date. The company also provided a positive clinical update, noting fewer disease progressions and deaths than projected in the ongoing blinded Phase 2 trial. This news provides crucial financial stability, addressing prior 'going concern' warnings and allowing the company to reach a significant clinical milestone without immediate funding pressure. Investors will now closely watch for the mid-year 2026 primary DFS analysis for the AMPLIFY-7P trial and the subsequent End-of-Phase 2 meeting with the FDA.

At the time of this announcement, ELTX was trading at $11.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $217.2M. The 52-week trading range was $5.15 to $14.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ELTX - Latest Insights

ELTX
Nov 05, 2026, 4:14 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.41
Real-time Price: $1.36 info
Change: -$0.045 (-3%) info
Market Cap: $37.928M info
ELTX
Nov 05, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $1.36 info
Change: -$0.045 (-3%) info
Market Cap: $37.928M info
ELTX
Oct 23, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.78
Real-time Price: $1.36 info
Change: -$0.420 (-24%) info
Market Cap: $37.928M info
ELTX
Aug 13, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $1.36 info
Change: -$1.74 (-56%) info
Market Cap: $37.928M info
ELTX
Jul 06, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $1.36 info
Change: -$1.90 (-58%) info
Market Cap: $37.928M info